Sheena Patel, PA
Psychiatric/Mental Health, Adult · Costa Mesa, CANPI 1932454709
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $131,971 of the $202,068 with a category attached, or 65.3%. 43 manufacturers reported payments, led by Johnson & Johnson at 45.7% of the total. Reporting peaked in 2023 at $72,767 and has fallen 92.7% since, to $5,287 in 2025. Among psychiatric/mental health, adult clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,264 payments — averaging $159.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$92K
- AbbVie$64K
- Otsuka America Pharmaceutical, Inc.$22K
- Alkermes, Inc.$6K
- Teva Pharmaceuticals USA, Inc.$3K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$3K
- plus $12K from 37 others
What the payments were for
- Consulting fees$11,8936%
- Speaking & faculty fees$131,97165%
- Travel & lodging$28,79014%
- Food & beverage$29,31315%
- Education$1000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INVEGA SUSTENNA$86,434
- INVEGA TRINZA$85,499
- VRAYLAR$59,142
- REXULTI$20,166
- LYBALVI$18,644
- SPRAVATO$1,825
- ARISTADA$971
- AUSTEDO$597
- ARISTADA INITIO$243
- INGREZZA$239
- Auvelity$237
- NEUROSTAR TMS THERAPY SYSTEM$157
- INVEGA$127
- CAPLYTA$125
- Austedo XR$120
- Phasix Mesh$106
- QUVIVIQ$101
How this compares
$202,068 in reported general payments places this provider in the 95th percentile of 47 psychiatric/mental health, adult providers in California.
See all psychiatric/mental health, adult providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 11 | $92,904 |
| RexultiBrexpiprazole | 27 | $40,280 |
| VraylarCariprazine Hcl | 26 | $36,826 |
| Invega SustennaPaliperidone Palmitate | 15 | $35,425 |
| Risperdal ConstaRisperidone Microspheres | 24 | $14,505 |
| AuvelityDextromethorphan Hbr/Bupropion | 12 | $7,956 |
| TrintellixVortioxetine Hydrobromide | 13 | $6,027 |
| VyvanseLisdexamfetamine Dimesylate | 13 | $5,147 |
| Bupropion XlBupropion Hcl | 105 | $1,620 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 39 | $1,431 |
| Duloxetine Hcl | 78 | $892 |
| Quetiapine Fumarate | 78 | $777 |
| Aripiprazole | 18 | $754 |
| Amitriptyline Hcl | 17 | $670 |
| Lurasidone Hcl | 26 | $495 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $1,580 | $92,90411 claims |
| Johnson & JohnsonInvega Sustenna, Risperdal Consta | $92,277 | $49,93039 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $22,177 | $40,28027 claims |
| AbbVieVraylar | $64,380 | $36,82626 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $288 | $11,17426 claims |
| Axsome Therapeutics, Inc.Auvelity | $609 | $7,95612 claims |
| Almatica Pharma LLCSertraline Hcl | $235 | $23464 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 47 psychiatric/mental health, adult providers in California.
Other psychiatric/mental health, adult in Costa Mesa
- Taryn JoyceSan Pedro$4K
- Paula CarmonaSan Diego$750
- Cynthia ChesyNational City$750
- Priscilla VargaBurbank$519
- Anika SimpsonLos Angeles$516
- Jeannette DeanoSan Francisco$509
- Vivian VorceLompoc$466
- Roberto SantoyoVisalia$366
- Jeanne TemplemanSacramento$316
- Shirley HollowellStockton$299
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.